2019 sees the biosimilars market reach teenage status. How will this influence future market growth?
Can positive experiences learned during the early years of growth be leveraged for continued future market success? Or have we seen the best that the market has to offer?
In April 2006, Sandoz received European Medicines Agency (EMA) approval for Omnitrope, its biosimilar version of the somatropin…
To continue reading this article, please visit IQPC’s biosimilars blog page. While you’re there you could also download the agenda for their forthcoming Biosimilars Commercialisation Summit (Amsterdam; May 14-16, 2019).